Treatment Selection Choices Should Not Be Based on Benefits or Costs Alone: A Head-to-Head Randomized Controlled Trial of Antiviral Drugs for Hepatitis C

por Davitkov, Perica, Chandar, Apoorva Krishna, Hirsch, Amy, Compan, Anita, Silveira, Marina G., Anthony, Donald D., Smith, Suzanne, Gideon, Clare, Bonomo, Robert A., Falck-Ytter, Yngve
Publicado en PLoS One (2016)

Soluble Markers of Immune Activation Differentially Normalize and Selectively Associate with Improvement in AST, ALT, Albumin, and Transient Elastography During IFN-Free HCV Therap...

por Kostadinova, Lenche, Shive, Carey L., Zebrowski, Elizabeth, Fuller, Brianna, Rife, Kelsey, Hirsch, Amy, Compan, Anita, Moreland, Anita, Falck-Ytter, Yngve, Popkin, Daniel L., Anthony, Donald D.
Publicado en Pathog Immun (2018)

Genetically Associated CD16(+)56(−) Natural Killer Cell Interferon (IFN)–αR Expression Regulates Signaling and Is Implicated in IFN-α–Induced Hepatitis C Virus Decline

por Conry, Sara J., Meng, Qinglai, Hardy, Gareth, Yonkers, Nicole L., Sugalski, Julia M., Hirsch, Amy, Davitkov, Perica, Compan, Anita, Falck-Ytter, Yngve, Blanton, Ronald E., Rodriguez, Benigno, Harding, Clifford V., Anthony, Donald D.
Publicado 2012

During Hepatitis C Virus (HCV) Infection and HCV-HIV Coinfection, an Elevated Plasma Level of Autotaxin Is Associated With Lysophosphatidic Acid and Markers of Immune Activation Th...

por Kostadinova, Lenche, Shive, Carey L., Judge, Chelsey, Zebrowski, Elizabeth, Compan, Anita, Rife, Kelsey, Hirsch, Amy, Falck-Ytter, Yngve, Schlatzer, Daniela M., Li, Xiaolin, Chance, Mark R., Rodriguez, Benigno, Popkin, Daniel L, Anthony, Donald D.
Publicado en J Infect Dis (2016)